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Background/aim: Despite the use of ultrasound guidance, a significant part of thyroid biopsies are nondiagnostic (ND). We aimed
to investigate the utility of the preoperative modified systemic inflammation score (mSIS) to predict malignancies in patients with
persistent ND thyroid nodules (TNs).
Materials and methods: Records of 924 patients underwent thyroidectomy between September 2016 and May 2019 were retrospectively
reviewed. The calculation of mSIS was as follows: mSIS 0 [patients with albumin (ALB) ≥ 4.0 g/dL and lymphocyte to monocyte ratio
(LMR) ≥ 3.4], mSIS 1 [ALB < 4.0 g/dL or LMR < 3.4], and mSIS 2 [ALB < 4.0 g/dL and LMR < 3.4].
Results: One hundred and thirty-six patients were included in the study. Of the patients with a median age of 49 (21–81) years, 26
(19.1%) were male, and 110 (80.9%) were female. Besides low lymphocyte count (P = 0.03), and ALB levels (P < 0.01), higher BMI (P
= 0.02) were also associated with malignancy. In patients classified as mSIS 2, 1 and 0; malignancy rates were 100%, 25.8%, and 16.1%,
respectively. The association between preoperative mSIS and thyroid malignancies was statistically significant (P < 0.01).
Conclusion: We recommend that when patients with persistent ND TNs are assigned to mSIS 2 or 1, surgery should not be delayed
due to the risk of malignancy.
Key words: Systemic inflammation score, thyroid nodules, malignancy, nondiagnostic, lymphocyte to monocyte ratio

1. Introduction
Nodular disease of the thyroid gland is common in the
community. The incidence of nodules in areas where the
disease is endemic can be even more than 50% in high
resolution ultrasound (US) examinations [1]. Cytological
evaluation is still the most reliable method for suspicious
nodules undergoing ultrasound-guided fine needle
aspiration (FNA) biopsy to determine the malignancy risk
and decision making for surgery. The Bethesda system
has been used for this purpose for over ten years and
categorizes cytological results according to malignancy
risk [2]. However, it may not always be possible to state
clearly whether the nodules are benign or malignant
as a result of cytological examinations. The Bethesda I
category includes inadequate cytological results reported
as unsatisfactory or nondiagnostic (ND). The incidence
of ND cytology is reported in the literature, ranging
from 3% to 36.4% [3]. In cases with ND cytology, the
estimated overall risk of malignancy is 5%–10%, while

this rate is 9%–32% in surgically treated ones [2]. The first
recommendation for patients with ND thyroid nodules
(TNs) is to repeat FNA, but in the case of persistent (at
least two FNAs) ND cytological results, the clinical
features and sonographic findings of the nodules usually
determine the clinician’s decision [1,2]. Consequently,
the management of persistent ND TNs is often a cause
of concern for clinicians, and there is no consensus on
whether clinical follow-up or thyroidectomy is the most
appropriate approach. Hence, new modalities are needed
to distinguish malignant thyroid lesions from benign ones
preoperatively, especially for patients with persistent ND
nodules.
In the last decade, many studies have been published
showing that inflammation plays a crucial role in the
development of many types of cancer, including the
thyroid [4,5]. Increased thyroid cancer (TC) development
in cases of lymphocytic thyroiditis and the effect of
immune mechanisms on malignant transformation have
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been the focus of many articles [4–6]. As such, it is widely
believed that measuring of acute phase reactants and
certain leukocyte fractions in the blood can be used in
the diagnosis of cancer and predicting prognosis [6–8].
Particularly, an increase in serum C-reactive protein
(CRP) and decreased levels of serum albumin (ALB)
are considered markers of inflammation. These two
parameters are the main variables of the modified Glasgow
prognostic score used to predict prognosis in colon cancer
cases [9]. In addition to serum CRP and ALB, various
ratios calculated by circulating leukocyte subgroups
such as neutrophil to lymphocyte ratio and lymphocyte
to monocyte ratio (LMR) were also evaluated in terms
of possible associations with different malignancies [10].
Nevertheless, for patients with TNs, a viable scoring
system that could predict thyroid malignancies or a marker
evaluated in serum is not currently in use. The systemic
inflammation score (both modified and original version)
calculated using the preoperative ALB and LMR has been
used to evaluate the prognosis in patients with different
malignancies and reported to be useful [11,12]. Moreover,
a recent study we have conducted provided evidence
that modified systemic inflammation score (mSIS) may
be useful in predicting malignancy in patients with
cytologically indeterminate TNs [13]. Even so, obtained
evidence needs to be confirmed in larger case series.
We aimed to investigate the utility of the preoperative
mSIS to predict malignancies in patients with persistent
ND TNs.
2. Material and methods
From September 2016 to May 2019, the records of
924 patients who received thyroidectomy for different
indications at the endocrine surgery department of our
hospital were retrospectively reviewed. Out of 924 patients,
136 patients with ≥2 ND cytological results were included
in the study. ND TNs with subsequent different cytologies
were excluded from the study.
All FNAs were performed with a 25–27 gauge needle
and 20 mL syringe under US guidance by experienced
endocrinologists. Consecutive FNA procedures were
performed with an average interval of 3 months. The
specimens were not evaluated on-site for sufficiency. FNA
samples were evaluated by cytopathologists according to
the Bethesda system, and specimens showing less than
six groups of cells that consisted of less than ten cells
each group were defined as ND. Patients with nodules
larger than 4 cm in diameter, those who had previously
received radiation to the neck region, and those with
histopathologically proven thyroiditis were excluded from
the study. Other exclusion criteria were as follows; active
infection in the last three months, steroid use, systemic
inflammatory diseases such as Crohn’s or ulcerative

colitis, liver failure, other cancer, renal failure, and acute
myocardial infarction in the last six months. The patients
included in the study were divided into two groups named
malignant and benign, considering the final pathology
results. Demographic data such as age, sex, body mass
index (BMI), which were thought to be associated with
the development of malignancy, and preoperative thyroidstimulating hormone (TSH), white blood cell counts, ALB
and thyroid volume (TV) data were recorded. The formulas
used for variables that require special calculations were
as follows; BMI = weight (kg) / height squared (m2), TV
(elliptical shape volume) = Length × width × height × 0.479
(for each lobe) and LMR = total count of lymphocytes /
total count of monocytes. Blood samples were collected
following a fast for at least 8 h and studied over a 30-min
period. The mSIS was calculated for patients following
the determination of malignancy-related variables. The
formulation for mSIS was as below [12].
ALB ≥ 4.0 g/dL and LMR ≥ 3.4 →mSIS 0
ALB < 4.0 g/dL or LMR < 3.4 →mSIS 1
ALB < 4.0 g/dL and LMR <3.4 →mSIS 2
Then, patients were divided into three groups according
to the number of mSIS, and the relationship between
changing score and malignancy was statistically evaluated.
2.1. Statistical analysis
Statistical analyses were performed using IBM Statistical
Package for the Social Sciences version 21 (IBM SPSS
Corp.; Armonk, NY, USA). The Kolmogorov–Smirnov
and Levene’s tests were used to assess the normality and
the homogeneity of data distribution, respectively. The
mean ± standard deviation (SD) values were used to
describe for normally distributed continuous variables,
and median (min-max) were used for nonnormally
distributed ones. Differences in continuous variables were
analyzed using the Student’s t-test, Mann–Whitney U
test, or Kruskal–Wallis test, χ2 tests or Fisher’s exact test
were used to analyze the categorical variables. The binary
logistic regression method was used to evaluate the factors
affecting malignancy. The variables that significantly affect
the pathology results in univariate analyses and variables
that make a significant difference in the literature were
included in the model. Variables showing multicollinearity
were not included in the model. Statistical significance was
calculated at the 95% confidence interval, and a P-value
<0.05 were considered significant for the presented results.
3. Results
Fine needle aspiration cytology (FNAC) results were
persistent ND in 147 (15.9%) of 924 patients undergoing
thyroidectomy. However, eleven patients were excluded
from the study due to a history of malignancy, renal failure,
and the presence of inflammatory diseases. One hundred
and thirty-six patients were included in the study and the
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median age was 49 (21–81) years. Of these, 26 (19.1%)
were male and 110 (80.9%) were female. The median value
for the patients’ BMI was 28.8 (19.7–45.5) kg/m2. The
mean size of the ND nodules’ was 15.30 ± 0.95 mm (9–39
mm). While thyroidectomy was performed in 115 cases
totally, only 21 cases underwent lobectomy. As a result
of histopathological evaluation of surgical specimens,
39 patients (28.6%) were diagnosed as malignant.
Micropapillary carcinoma was identified in 10 patients
(25.6%), papillary carcinomain 27 patients (69.2%) and
follicular carcinoma in 2 patients (5.2%). Demographic
and laboratory data of benign and malignant groups are
presented in Table 1.
In univariate (UV) analyses, there was no difference
between benign and malignant groups in terms of age and
sex. However, it was striking that in the malignant group,
BMI was significantly higher (P = 0.02), and ALB values
and lymphocyte count were significantly lower (P < 0.01
and P = 0.03, respectively). According to the results of UV
analysis, a model was created for multivariate analysis. It
was found that LMR statistically affected the pathology
results if the effects of BMI and ALB on pathology results
were controlled (OR: 0.66, 95% CI: 0.45–0.95) (Table 2).
Of 136 patients with persistent ND cytology, 87
(63.9%) were assigned as mSIS 0, 35 (25.8%) as mSIS 1
and 14 (10.3%) as mSIS 2. In patients classified as mSIS 2,
1 and 0; malignancy rates were 100%, 25.8%, and 16.1%,
respectively. The malignancy rate was significantly higher
in mSIS 2 group compared to mSIS 1 and 0 group (P <

0.01); however, tumor size did not differ between the mSIS
groups (P = 0.89) (Table 3, Figure). The parameters for the
validity of mSIS in predicting malignancy for different risk
groups are presented in Table 4.
4. Discussion
The management of persistent ND TNs is often
controversial. International guidelines recommend
repeating FNAC with ultrasound guidance or excision
with diagnostic surgery, which is generally in favor of
lobectomy [2]. However, since the majority of ND nodules
are not removed, it is difficult to calculate and interpret
the risk of malignancy. This is another reason for the with
controversy over the extent of the surgery to be performed.
Therefore, in addition to cytological evaluation and US
features, it is obvious that a new diagnostic scoring method
is needed to predict the malignancy risk of ND nodules
and to decide the most appropriate one from surgical and
follow-up options.
Given the relationship between inflammation
and carcinogenesis, the idea that blood markers of
inflammation can also be used as a biomarker for cancer
diagnosis and post-treatment follow-up is not far off
[4,5,8]. However, most of the studies to date show that
inflammation markers are used to determine the prognosis
of TC, and the number of studies focusing on the diagnosis
of the disease is very few [6,7]. In the current study, the
malignancy rate of patients with ND nodules who had
only histological follow-ups and surgically treated was

Table 1. Univariate analyses for benign and malignant groups.
Characteristics

Benign (n = 97)
n (%)*

Malignant (n = 39)
n (%)*

P-value

Age (years)

49 (21–71)

48.5 (26–81)

0.58§

Sex
Female
Male

81 (83.5)
16 (16.5)

29 (74.4)
10 (25.6)

0.22‡

BMI (kg/m2)

28.3 (19.9–40.6)

31.4 (19.7–45.5)

0.02§

Thyroid volume, mL

43.1 ± 35.9

46.2 ± 39.7

0.91†

TSH, mIU/mL

1.1 ± 0.8

1.3 ± 1.2

0.57†

Lymphocyte (/µL)

2.2 (1.2–5.9)

1.9 (0.8–3.4)

0.03§

Monocyte (/µL)

0.4 ± 0.1

0.5 ± 0.1

0.09†

LMR

5.6 ± 4.9

3.8 ± 1.4

0.05†

ALB, g/dL

4.3 (3.4–5.1)

3.9 (3.7–4.7)

<0.01§

*
Mean ± standard deviation for a normally distributed continuous variable, median (minmax) for nonnormally distributed continuous variables were demonstrated.
†
Student’s t-test, ‡χ2 tests, §Mann–Whitney U test.
BMI: body mass index, TSH: thyroid-stimulating hormone, LMR: lymphocyte to
monocyte ratio, ALB: albumin.
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Table 2. Multivariate analyses of the parameters affecting
pathology results.
Odds ratio

95% CI

P-value*

BMI (kg/m )

1.12

1.03–1.23

0.01

ALB (g/dL)

0.05

0.01–0.26

< 0.01

LMR

0.66

0.45–0.95

0.02

2

*Binary logistic regression.
CI: confidence interval.

28.6%. The rate we found was in accordance with the rate
of malignancy reported in the literature for resected ND
nodules [2]. We used mSIS in our study to predict the
presence of cancer. We demonstrated that the preoperative
score and malignancy rates correlated in patients with
ND nodules. We even found that all patients with mSIS
2 had malignancy. The feature of mSIS is that it evaluates
three important components (ALB, lymphocyte and
monocyte) that are predicted to be related to inflammation
and carcinogenesis. When inflammation becomes
chronic, ALB synthesis is reduced in the liver, indicating
malnutrition and cachexia in cancer cases [14,15]. Also,
lymphocytes are very important in cancer immunity,
and their decrease in number is associated with a poor
prognosis. Another important issue is the decrease in the
number of monocytes that differentiate into macrophages
in circulation and accelerate cancer development by
contributing to vascularization, growth and metastasis of
the tumor [4,16]. As a result, mSIS calculated using ALB
and LMR can accurately reflect the immune response that
points out carcinogenesis.

In a recent article, researchers demonstrated the
relationship between ALB level below 40 g/L and thyroid
malignancies, however, this relationship was not observed
for white blood cells, haptoglobin and CRP [17]. A study
conducted to distinguish TCs from benign nodules
provided evidence that both increased platelet distribution
width (PDW) and low ALB level may be associated
with TCs [7]. Another study revealed that decreased
LMR might be associated with increased recurrence in
differentiated thyroid malignancies [8]. Several authors
have suggested that low ALB levels may be associated with
thyroid malignancies. However, different and discrepant
results on other inflammation markers suggest that there
is still no consensus on this issue.
In literature, many studies aiming to predict
preoperative malignancy in patients with ND TNs are
generally concentrated on Thyroid imaging reporting
and data system (TI-RADS) [3,18]. In their study of
246 patients with persistent ND TNs, Başer et al. could
not reveal any suspicious ultrasonographic features for
predicting malignancy or did not point out any difference
between benign and malignant nodules in terms of TIRADS scores [3]. However, Yoon et al. concluded that the
malignancy risk stratification with TIRADS for ND TNs is
more effective than the Bethesda system. Their suggestion
was to follow-up with US-guided FNAC for TNs with
TIRADS category 4b, 4c, or 5. Nevertheless, they could
not provide an acceptable new recommendation for
estimating malignancy risk for patients with persistent ND
TNs [18].
Another point revealed by the present study was that
one of the factors associated with malignancy in patients
with persistent ND TNs was high BMI. Another point
revealed by this study is that a high BMI of patients with

Table 3. Comparison of final pathology results according to the modified systemic inflammation score
(mSIS).
mSIS 0
n (%)*

mSIS 1
n (%)*

mSIS 2
n (%)*

Benign

73 (83.9)

24 (68.6)

0 (0.0)

Malignant

14 (16.1)

11 (31.4)

14 (100.0)

Malignant tumor diameter (mm)

11.5 (9–23)

14.0 (9–28)

13.5 (10–39)

Microcancer

4 (28.6)

3 (27.3)

3 (21.4)

Macrocancer

10 (71.4)

8 (72.7)

11 (78.6)

P-value

Final pathology results
<0.01†
0.89‡

Malignant tumor classification (n = 39)
0.90†

* Median (min-max) for nonnormally distributed continuous variables were demonstrated.
†
χ2 tests,‡Kruskal–Wallis test.
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Figure. Distribution of pathology results by mSIS groups.
Table 4. The parameters for the validity of mSIS in predicting malignancy for different risk groups.
High-risk default group for malignancy

Sensitivity
(%)

Specificity
(%)

PPV
(%)

NPV
(%)

Accuracy rate (%)

mSIS 1 or 2

64

75

51

84

72

mSIS 2

35

100

100

79

82

PPV: positive predictive value, NPV: negative predictive value.

persistent ND nodules is another factor associated with thyroid malignancies. Recently, some authors have published a
quite large series showing the positive association between higher BMI and TC risk [19]. However, there is no sufficient
data in the literature that higher BMI increases malignancy in patients with persistent ND TNs. Therefore, it is obvious that
new studies will clarify whether BMI is a risk factor associated with malignant transformation of ND TNs.
The limitations of this study can be expressed as follows. First, the study design is retrospective, and the sample size is
small since only patients with persistent ND nodules are included. Therefore, this situation may have reduced the statistical
power of some subgroup analyzes. Another important point is that it is unavailable due to the retrospective nature of the
study and is likely to affect mSIS data such as diet and drug use.
In our study, we evaluated the patients who underwent thyroid surgery due to both suspicious ultrasound findings
(such as solidity, hypoechogenicity, irregular margins, taller-than-wide shape, and microcalcifications) and persistent ND
cytology. Therefore, the results we obtained should not be generalized for all patients with ND cytology. However, to our
knowledge, our study is the first report in the literature that provides evidence between mSIS and the malignancy risk of
persistent ND TNs. The patients included in the study belong to the most controversial and challenging category of the
Bethesda classification. In this respect, the results obtained from our study will contribute significantly to clinicians and
endocrine surgeons in decision making.
In conclusion, this study indicates that high mSIS in patients with persistent ND cytology may be associated with
thyroid malignancies. Although promising in terms of specificity, mSIS may not be considered as an ideal scoring to be
used alone to predict the presence of malignancy as its sensitivity is not high enough. Nevertheless, due to its low cost and
easy applicability, mSIS can be used as an adjunctive method to determine the malignancy riskof persistent ND nodules.
Our results strongly support that, because of the increased risk of malignancy, surgery should not be delayed if patients
with persistent ND TNs are assigned to mSIS 2 or 1, particularly in endemic goiter regions. Even so, further studies are
needed to confirm these preliminary results.
Disclaimer/conflict of interest
The authors declare no conflict of interest. No funding has been received for this paper.

704

ATAŞ et al. / Turk J Med Sci
Informed consent
This study was approved by the Institutional Review Board
of Ankara City Hospital Ethics Committee (Number:
E-1-20-697;May 28, 2020). Informed consent was taken

from all patients during the registration. All procedures in
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in accordance with the 1964 Helsinki Declaration and its
later amendments.
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